Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 4/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 4/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.36 |
| ▸ | HTR5A | P47898 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | MTHFD2 | P13995 | 2/20 | 0.36 |
| ▸ | CFTR | P13569 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL989561 | 0.93 | MCHR1 (0.38) | MCHR1BAZ2BHDAC10HDAC6HDAC8 | |
| SCHEMBL1006858 | 0.91 | MCHR1 (0.38) | MCHR1BAZ2BHDAC10HDAC6HDAC8 | |
| SCHEMBL9930853 | 0.83 | DDB1 (0.47) | MCHR1BAZ2BHDAC10HDAC6HDAC1 | |
| SCHEMBL16942538 | 0.81 | HTR5A (0.48) | MCHR1HDAC10HDAC6HDAC8HTR5A | |
| SCHEMBL18381082 | 0.80 | CYP1A2 (0.35) | MCHR1BAZ2BHDAC10HDAC6HDAC8 | |
| SCHEMBL21588383 | 0.79 | HDAC1 (0.36) | MCHR1BAZ2BHDAC6HDAC1 | |
| SCHEMBL1004761 | 0.77 | DDB1 (0.40) | HDAC6HDAC1 | |
| SCHEMBL30339918 | 0.77 | DDB1 (0.40) | HDAC6HDAC1 | |
| SCHEMBL989533 | 0.77 | DDB1 (0.42) | MCHR1HDAC6HDAC1 | |
| SCHEMBL3477090 | 0.77 | BAZ2B (0.53) | MCHR1BAZ2BHDAC10HDAC6HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993765-B2 | Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| WO-2012088124-A2 | TETRAHYDRO-AZACARBOLINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120157460-A1 | TETRAHYDRO-AZACARBOLINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157460-A1 | TETRAHYDRO-AZACARBOLINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USES THEREOF | MCHR1, MCHR2, MC5R | MCHR1 1/4885BAZ2B 2409/4885HDAC10 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.